Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 97

1.

Efficiency of Steel Corrosion Inhibitors in an Environment of Ethanol-Gasoline Blends.

Matějovský L, Macák J, Pleyer O, Straka P, Staš M.

ACS Omega. 2019 May 17;4(5):8650-8660. doi: 10.1021/acsomega.8b03686. eCollection 2019 May 31.

2.

Solar Lentigines are Associated with Better Outcome in Cutaneous Melanoma.

Marasigan V, Güvenç C, Oord JJ, Stas M, Boecxstaens V, Bechter O, Wolter P, Lambrechts D, Garmyn M.

Acta Derm Venereol. 2019 Jul 17. doi: 10.2340/00015555-3270. [Epub ahead of print]

3.

Gelatinase B/matrix metalloproteinase-9 and other neutrophil proteases switch off interleukin-2 activity.

Rybakin V, Stas M, Ugarte-Berzal E, Noppen S, Vandooren J, Van Aelst I, Liekens S, Proost P, Opdenakker G.

Biochem J. 2019 Aug 9;476(15):2191-2208. doi: 10.1042/BCJ20180382.

PMID:
31262730
4.

Microscopic Revelation of Charge-Trapping Sites in Polymeric Carbon Nitrides for Enhanced Photocatalytic Activity by Correlating with Chemical and Electronic Structures.

Nimbalkar DB, Stas M, Hou SS, Ke SC, Wu JJ.

ACS Appl Mater Interfaces. 2019 May 29;11(21):19087-19095. doi: 10.1021/acsami.9b02494. Epub 2019 May 15.

PMID:
31062573
5.

Establishment and Characterization of Histologically and Molecularly Stable Soft-tissue Sarcoma Xenograft Models for Biological Studies and Preclinical Drug Testing.

Cornillie J, Wozniak A, Li H, Wang Y, Boeckx B, Gebreyohannes YK, Wellens J, Vanleeuw U, Hompes D, Stas M, Sinnaeve F, Wafa H, Lambrechts D, Debiec-Rychter M, Sciot R, Schöffski P.

Mol Cancer Ther. 2019 Jun;18(6):1168-1178. doi: 10.1158/1535-7163.MCT-18-1045. Epub 2019 Apr 8.

PMID:
30962320
6.

Melanoma susceptibility variant rs869330 in the MTAP gene is associated with melanoma outcome.

Marasigan V, Güvenç C, van den Oord JJ, Stas M, Boecxstaens V, Bechter O, Wolter P, Lambrechts D, Garmyn M.

Melanoma Res. 2019 Jan 23. doi: 10.1097/CMR.0000000000000578. [Epub ahead of print]

PMID:
30681428
7.

Metal Corrosion and the Efficiency of Corrosion Inhibitors in Less Conductive Media.

Matějovský L, Macák J, Pleyer O, Staš M.

J Vis Exp. 2018 Nov 3;(141). doi: 10.3791/57757.

PMID:
30451241
8.

Rare cause of cerebrovascular event.

Balthazar T, Scheurwegs C, Stas M, Budts W.

Acta Cardiol. 2019 Aug;74(4):363-364. doi: 10.1080/00015385.2018.1494794. Epub 2018 Sep 27. No abstract available.

PMID:
30259791
9.

SecurAstaP trial: securement with SecurAcath versus StatLock for peripherally inserted central catheters, a randomised open trial.

Goossens GA, Grumiaux N, Janssens C, Jérôme M, Fieuws S, Moons P, Stas M, Maleux G.

BMJ Open. 2018 Feb 24;8(2):e016058. doi: 10.1136/bmjopen-2017-016058.

10.

Vitamin D supplementation in cutaneous malignant melanoma outcome (ViDMe): a randomized controlled trial.

De Smedt J, Van Kelst S, Boecxstaens V, Stas M, Bogaerts K, Vanderschueren D, Aura C, Vandenberghe K, Lambrechts D, Wolter P, Bechter O, Nikkels A, Strobbe T, Emri G, Marasigan V, Garmyn M.

BMC Cancer. 2017 Aug 23;17(1):562. doi: 10.1186/s12885-017-3538-4.

11.

Response to targeted therapy in two patients with metastatic melanoma carrying rare BRAF exon 15 mutations: A598_T599insV and V600_K601delinsE.

Rogiers A, Vander Borght S, Tuand K, Wolter P, Stas M, Boecxstaens V, Garmyn M, van den Oord JJ, Vandenberghe P, Bechter O.

Melanoma Res. 2017 Oct;27(5):507-510. doi: 10.1097/CMR.0000000000000376.

PMID:
28800030
12.

Successful forearm prosthesis fitting in a patient with epidermolysis bullosa dystrophica: Case report.

Verduyn C, Morren MA, Stas M, Sinnaeve F, Segers K, Kiekens C.

Prosthet Orthot Int. 2018 Jun;42(3):254-257. doi: 10.1177/0309364617718410. Epub 2017 Jul 20.

PMID:
28726572
13.

Improving outcomes of short peripheral vascular access in oncology and chemotherapy administration.

Bertoglio S, van Boxtel T, Goossens GA, Dougherty L, Furtwangler R, Lennan E, Pittiruti M, Sjovall K, Stas M.

J Vasc Access. 2017 Mar 21;18(2):89-96. doi: 10.5301/jva.5000668. Epub 2017 Jan 25. Review.

PMID:
28127726
14.

Gas-Phase Synthesis of the Elusive Trisilicontetrahydride Species (Si3H4).

Yang T, Dangi BB, Thomas AM, Kaiser RI, Sun BJ, Staś M, Chang AH.

J Phys Chem Lett. 2017 Jan 5;8(1):131-136. doi: 10.1021/acs.jpclett.6b02710. Epub 2016 Dec 16.

PMID:
27959543
15.

Conformational preferences and synthesis of isomers Z and E of oxazole-dehydrophenylalanine.

Staś M, Bujak M, Broda MA, Siodłak D.

Biopolymers. 2016 May;106(3):283-94. doi: 10.1002/bip.22852.

PMID:
27061820
16.

Plasma cells in primary melanoma. Prognostic significance and possible role of IgA.

Bosisio FM, Wilmott JS, Volders N, Mercier M, Wouters J, Stas M, Blokx WA, Massi D, Thompson JF, Scolyer RA, van Baren N, van den Oord JJ.

Mod Pathol. 2016 Apr;29(4):347-58. doi: 10.1038/modpathol.2016.28. Epub 2016 Feb 12.

17.

Novel Therapies for Metastatic Melanoma: An Update on Their Use in Older Patients.

Rogiers A, van den Oord JJ, Garmyn M, Stas M, Kenis C, Wildiers H, Marine JC, Wolter P.

Drugs Aging. 2015 Oct;32(10):821-34. doi: 10.1007/s40266-015-0304-7. Review.

PMID:
26442859
18.

Diagnostic accuracy of the Catheter Injection and Aspiration (CINAS) classification for assessing the function of totally implantable venous access devices.

Goossens GA, De Waele Y, Jérôme M, Fieuws S, Janssens C, Stas M, Moons P.

Support Care Cancer. 2016 Feb;24(2):755-761. doi: 10.1007/s00520-015-2839-x. Epub 2015 Jul 26.

PMID:
26209949
19.

Antitumor immunity triggered by melphalan is potentiated by melanoma cell surface-associated calreticulin.

Dudek-Perić AM, Ferreira GB, Muchowicz A, Wouters J, Prada N, Martin S, Kiviluoto S, Winiarska M, Boon L, Mathieu C, van den Oord J, Stas M, Gougeon ML, Golab J, Garg AD, Agostinis P.

Cancer Res. 2015 Apr 15;75(8):1603-14. doi: 10.1158/0008-5472.CAN-14-2089. Epub 2015 Mar 11.

20.

Pazopanib, a Receptor Tyrosine Kinase Inhibitor, Suppresses Tumor Growth through Angiogenesis in Dedifferentiated Liposarcoma Xenograft Models.

Li H, Wozniak A, Sciot R, Cornillie J, Wellens J, Van Looy T, Vanleeuw U, Stas M, Hompes D, Debiec-Rychter M, Schöffski P.

Transl Oncol. 2014 Dec;7(6):665-71. doi: 10.1016/j.tranon.2014.09.007.

21.

Bioaccumulation of hydroxylated polychlorinated biphenyls and pentachlorophenol in the serum of northern elephant seal pups (Mirounga angustirostris).

Louis C, Covaci A, Stas M, Crocker DE, Malarvannan G, Dirtu AC, Debier C.

Environ Res. 2015 Jan;136:441-8. doi: 10.1016/j.envres.2014.08.040. Epub 2014 Nov 25.

PMID:
25460666
22.

Mobilisation of lipophilic pollutants from blubber in northern elephant seal pups (Mirounga angustirostris) during the post-weaning fast.

Louis C, Dirtu AC, Stas M, Guiot Y, Malarvannan G, Das K, Costa DP, Crocker DE, Covaci A, Debier C.

Environ Res. 2014 Jul;132:438-48. doi: 10.1016/j.envres.2014.04.016. Epub 2014 May 21.

23.

Cutaneous adverse effects of BRAF inhibitors in metastatic malignant melanoma, a prospective study in 20 patients.

Vanneste L, Wolter P, Van den Oord JJ, Stas M, Garmyn M.

J Eur Acad Dermatol Venereol. 2015 Jan;29(1):61-8. doi: 10.1111/jdv.12449. Epub 2014 Mar 24.

PMID:
24661317
24.

Conformational properties of oxazole-amino acids: effect of the intramolecular N-H···N hydrogen bond.

Siodłak D, Staś M, Broda MA, Bujak M, Lis T.

J Phys Chem B. 2014 Mar 6;118(9):2340-50. doi: 10.1021/jp4121673. Epub 2014 Feb 25.

PMID:
24528177
25.

A novel hypoxia-associated subset of FN1 high MITF low melanoma cells: identification, characterization, and prognostic value.

Wouters J, Stas M, Govaere O, Barrette K, Dudek A, Vankelecom H, Haydu LE, Thompson JF, Scolyer RA, van den Oord JJ.

Mod Pathol. 2014 Aug;27(8):1088-100. doi: 10.1038/modpathol.2013.228. Epub 2014 Jan 3.

26.

The human melanoma side population displays molecular and functional characteristics of enriched chemoresistance and tumorigenesis.

Wouters J, Stas M, Gremeaux L, Govaere O, Van den Broeck A, Maes H, Agostinis P, Roskams T, van den Oord JJ, Vankelecom H.

PLoS One. 2013 Oct 3;8(10):e76550. doi: 10.1371/journal.pone.0076550. eCollection 2013.

27.

Genome-wide promoter methylation analysis identifies epigenetic silencing of MAPK13 in primary cutaneous melanoma.

Gao L, Smit MA, van den Oord JJ, Goeman JJ, Verdegaal EM, van der Burg SH, Stas M, Beck S, Gruis NA, Tensen CP, Willemze R, Peeper DS, van Doorn R.

Pigment Cell Melanoma Res. 2013 Jul;26(4):542-54. doi: 10.1111/pcmr.12096. Epub 2013 Apr 17.

PMID:
23590314
28.

Comparing normal saline versus diluted heparin to lock non-valved totally implantable venous access devices in cancer patients: a randomised, non-inferiority, open trial.

Goossens GA, Jérôme M, Janssens C, Peetermans WE, Fieuws S, Moons P, Verschakelen J, Peerlinck K, Jacquemin M, Stas M.

Ann Oncol. 2013 Jul;24(7):1892-9. doi: 10.1093/annonc/mdt114. Epub 2013 Apr 3.

PMID:
23553060
29.

Access of a fully rotated implantable port leads to extravasation.

Goossens GA, Kerschaever I, Despierre E, Stas M.

J Vasc Access. 2013 Jul-Sep;14(3):299-300. doi: 10.5301/jva.5000136. Epub 2013 Jan 21. No abstract available.

PMID:
23543490
30.

Symptomatic tibial vein aneurysm - a diagnostic challenge.

T'Seyen S, Bertrand P, Goosens V, Stas M, Verhamme P, Maleux G.

Vasa. 2013 Jan;42(1):72-6. doi: 10.1024/0301-1526/a000239. No abstract available.

PMID:
23385229
31.

Management of venous access devices by Advanced Practice Nursing teams: more research needed.

Goossens GA, Stas M, Moons P.

Eur J Oncol Nurs. 2012 Dec;16(5):473-4. doi: 10.1016/j.ejon.2012.08.006. Epub 2012 Oct 3. No abstract available.

PMID:
23039923
32.

Loss of microRNA-200a and c, and microRNA-203 expression at the invasive front of primary cutaneous melanoma is associated with increased thickness and disease progression.

van Kempen LC, van den Hurk K, Lazar V, Michiels S, Winnepenninckx V, Stas M, Spatz A, van den Oord JJ.

Virchows Arch. 2012 Oct;461(4):441-8. doi: 10.1007/s00428-012-1309-9. Epub 2012 Sep 6.

PMID:
22956368
33.

Multiple granular cell tumors in a child with Noonan syndrome.

Bamps S, Oyen T, Legius E, Vandenoord J, Stas M.

Eur J Pediatr Surg. 2013 Jun;23(3):257-9. doi: 10.1055/s-0032-1322537. Epub 2012 Aug 22. No abstract available.

PMID:
22915371
34.

Extrapulmonary lymphangioleiomyomatosis: a wolf in sheep's clothing.

Derweduwen AM, Verbeken E, Stas M, Verschakelen J, Coolen J, Verleden G, Wuyts W.

Thorax. 2013 Jan;68(1):111-3. doi: 10.1136/thoraxjnl-2012-201973. Epub 2012 Aug 3.

PMID:
22863757
35.

Neogenesis of lymphoid structures and antibody responses occur in human melanoma metastases.

Cipponi A, Mercier M, Seremet T, Baurain JF, Théate I, van den Oord J, Stas M, Boon T, Coulie PG, van Baren N.

Cancer Res. 2012 Aug 15;72(16):3997-4007. Epub 2012 Jul 31.

36.

Gene expression changes in melanoma metastases in response to high-dose chemotherapy during isolated limb perfusion.

Wouters J, Stas M, Govaere O, Van den Eynde K, Vankelecom H, van den Oord JJ.

Pigment Cell Melanoma Res. 2012 Jul;25(4):454-65. doi: 10.1111/j.1755-148X.2012.01004.x. Epub 2012 May 3.

PMID:
22486811
37.

Administration of 24-h intravenous infusions of trabectedin in ambulatory patients with mesenchymal tumors via disposable elastomeric pumps: an effective and patient-friendly palliative treatment option.

Schöffski P, Cerbone L, Wolter P, De Wever I, Samson I, Dumez H, Clement P, Wildiers H, Stas M.

Onkologie. 2012;35(1-2):14-7. doi: 10.1159/000335879. Epub 2012 Jan 20.

PMID:
22310339
38.

Management of functional complications of totally implantable venous access devices by an advanced practice nursing team: 5 years of clinical experience.

Goossens GA, Stas M, Moons P.

Eur J Oncol Nurs. 2012 Dec;16(5):465-71. doi: 10.1016/j.ejon.2011.11.006. Epub 2012 Jan 21.

PMID:
22265937
39.

Lymph node biopsies in a general internal medicine department: algorithm or individualized decision-making?

Verbrugge FH, Stas M, Knockaert D, Tousseyn T, Vanderschueren S.

Acta Clin Belg. 2011 Jul-Aug;66(4):274-9.

PMID:
21938982
40.

Systematic review: malfunction of totally implantable venous access devices in cancer patients.

Goossens GA, Stas M, Jérôme M, Moons P.

Support Care Cancer. 2011 Jul;19(7):883-98. doi: 10.1007/s00520-011-1171-3. Epub 2011 May 10. Review.

PMID:
21556721
41.

GAVeCeLT* consensus statement on the correct use of totally implantable venous access devices for diagnostic radiology procedures.

Bonciarelli G, Batacchi S, Biffi R, Buononato M, Damascelli B, Ghibaudo F, Orsi F, Pittiruti M, Scoppettuolo G, Verzè A, Borasi G, De Cicco M, Dosio R, Gazzo P, Maso R, Roman A, Ticha V, Venier G, Blackburn P, Goossens GA, Bowen Santolucito J, Stas M, Van Boxtel T, Vesely TM, de Lutio E; Gruppo Aperto di Studio Accessi Venosi Centrali a Lungo Termine (Study Group on Long-Term Central Venous Access).

J Vasc Access. 2011 Oct-Dec;12(4):292-305. doi: 10.5301/JVA.2011.7736.

PMID:
21534233
42.

Feasibility and safety of endovascular stripping of totally implantable venous access devices.

Heye S, Maleux G, Goossens GA, Vaninbroukx J, Jerôme M, Stas M.

Cardiovasc Intervent Radiol. 2012 Jun;35(3):607-12. doi: 10.1007/s00270-011-0158-2. Epub 2011 Apr 9.

PMID:
21479744
43.

Sensory perceptions of patients with cancer undergoing surgical insertion of a totally implantable venous access device: a qualitative, exploratory study.

Goossens E, Goossens GA, Stas M, Janssens C, Jérôme M, Moons P.

Oncol Nurs Forum. 2011 Jan;38(1):E20-6. doi: 10.1188/11.ONF.E20-E26.

PMID:
21186148
44.

Prospective clinical evaluation of the Polyperf® Safe, a safety Huber needle, in cancer patients.

Goossens GA, Moons P, Jérôme M, Stas M.

J Vasc Access. 2011 Jul-Sep;12(3):200-6. doi: 10.5301/JVA.2010.6075.

PMID:
21104674
45.

Quality of life and disability after ilio-inguinal lymphadenectomy.

Brouns E, Donceel P, Stas M.

Acta Chir Belg. 2008 Nov-Dec;108(6):685-90.

PMID:
19241918
46.

A pilot trial of microplasmin in patients with long-term venous access catheter thrombosis.

Verhamme P, Jerome M, Goossens G, Devis J, Maleux G, Stas M.

J Thromb Thrombolysis. 2009 Nov;28(4):477-81. doi: 10.1007/s11239-009-0310-x. Epub 2009 Feb 19.

PMID:
19225865
47.

Radiation-induced sarcoma: analysis of 46 cases.

De Smet S, Vandermeeren L, Christiaens MR, Samson I, Stas M, Van Limbergen E, De Wever I.

Acta Chir Belg. 2008 Sep-Oct;108(5):574-9.

PMID:
19051469
48.

Functional evaluation of conventional 'Celsite' venous ports versus 'Vortex' ports with a tangential outlet: a prospective randomised pilot study.

Goossens GA, Verbeeck G, Moons P, Sermeus W, De Wever I, Stas M.

Support Care Cancer. 2008 Dec;16(12):1367-74. doi: 10.1007/s00520-008-0436-y. Epub 2008 Apr 15.

PMID:
18414904
49.

A dose-finding clinical trial of staphylokinase SY162 in patients with long-term venous access catheter thrombotic occlusion.

Verhamme P, Goossens G, Maleux G, Collen D, Stas M.

J Thromb Thrombolysis. 2007 Aug;24(1):1-5. Epub 2007 Feb 3.

PMID:
17278000
50.

Vacutainer filling time through subcutaneous venous access devices.

Goossens GA, Vrebos M, De Wever I, Stas M.

J Vasc Access. 2004 Oct-Dec;5(4):154-60.

PMID:
16596559

Supplemental Content

Support Center